NECTIN4 and colorectal cancer: In conclusion, we have demonstrated the antitumor effects of rMV-SLAMblind against nectin-4-positive colorectal cancer cells, including cells resistant to EGFR inhibitors, indicating that it is a potential novel therapy for colorectal cancers.